The latest announcement is out from PDS Biotechnology ( (PDSB) ).

Explore Vir Biotechnology (NASDAQ: VIR) operations in the healthcare sector and its presence in S&P 500, Nasdaq Composite, and Russell 1000 indexes, with detailed sector insights.

University of Liverpool and Newcastle researchers have uncovered how bacterial organelles assemble, opening new routes for ...

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms ...

A low-intensity ultrasound treatment clears neurotoxic debris from the brains of mice with induced bleeding that resembles a ...

Today is shaping up negative for Vir Biotechnology, Inc. ( NASDAQ:VIR ) shareholders, with the analysts delivering ...

Lab-made antivenom developed using recombinant technology can completely protect against the most lethal effects of elapid ...

PDS Biotechnology ( ($PDSB) ) has provided an update. On October 29, 2025, PDS Biotechnology announced its request for a meeting with the FDA to ...

The biotechnology sector continues to demonstrate its unforgiving nature as Ocugen navigates turbulent financial waters while ...

Researchers are working on microscopic, wireless chips that can travel through the bloodstream and self-implant in a targeted ...

至此，研究人员完成了一个完整的闭环验证：通过静脉注射，细胞-电子混合体能够自主导航并植入大脑深部的炎症区域；通过外部无创的光照，这些植入的微型设备能够精准地、焦灶性地激活周围的神经元。一个全新的、非手术的脑深部刺激范式就此诞生。

GNEprop从这片广阔的虚拟分子海洋中，筛选出了大约 ...